Prognosis, course of disease, and treatment of the spondyloarthropathies (Q37879332)

24 August 2017

1 reference

title

Prognosis, course of disease, and treatment of the spondyloarthropathies (English)

1 reference

24 August 2017

Leirisalo-Repo M

1

1 reference

24 August 2017

publication date

1 November 1998

1 reference

Rheumatic Diseases Clinics of North America

24 August 2017

published in

1 reference

24 August 2017

volume

24

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

737-51, viii

1 reference

Amplification of plasmid and chromosome chlamydia dna in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Chlamydia pneumoniae--a new causative agent of reactive arthritis and undifferentiated oligoarthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Second-line treatment in seronegative spondylarthropathies

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Evaluation of sulphasalazine in the treatment of spondyloarthropathies

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Sulphasalazine in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

The chronicity of symptoms and disability in Reiter's syndrome. An analysis of 131 consecutive patients

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Reiter's syndrome: long-term follow-up in relation to development of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Ankylosing spondylitis. Current drug treatment

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Yersinia antigens in synovial-fluid cells from patients with reactive arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Yersinia enterocolitica in the synovial membrane of patients with Yersinia-induced arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Antibiotics in Yersinia enterocolitica infections

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Persistence of Yersinia enterocolitica in man.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Postdysenteric reactive arthritis. A clinical and immunogenetic study following an outbreak of salmonellosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Reiter's Syndrome and Reactive Arthritis in Perspective

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

THE COURSE OF ESTABLISHED ANKYLOSING SPONDYLITIS AND THE EFFECTS OF SULPHASALAZTh OVER 3 YEARS

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Ultrastructural and molecular analyses of the persistence of Chlamydia trachomatis (serovar K) in human monocytes

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Frequent association of chlamydial infection with Reiter's syndrome.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Are antibiotics of any use in reactive arthritis?

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Long term prognosis of reactive salmonella arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Ten-year follow-up study of patients with Yersinia arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Follow-up study of Reiter's disease and reactive arthritis. Factors influencing the natural course and the prognosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

High frequency of silent inflammatory bowel disease in spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Reactive arthritis following an outbreak of Salmonella infection in Finland

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Outcome of possible ankylosing spondylitis in a 10 years' follow-up study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Association of gut inflammation with increased serum IgA class Klebsiella antibody concentrations in patients with axial ankylosing spondylitis (AS): implication for different aetiopathogenetic mechanisms for axial and peripheral AS?

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Antibodies to Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis in the sera of patients with axial and peripheral form of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Prognosis of inflammatory joint diseases. A three-year follow-up study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Chronic uro-polyarthritis in the male

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Reactive arthritis associated with Clostridium difficile pseudomembranous colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Reiter's syndrome: a follow-up study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Isolation of bedsoniae from the joints of patients with Reiter's syndrome.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Natural course and prognosis of HLA-B27-positive oligoarthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Immunoepidemiology of post-Salmonella reactive arthritis in a cohort of women

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Post-Salmonella reactive arthritis: late clinical sequelae in a point source cohort

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Chlamydial isolations and serology in Reiter's syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

Clinically silent infections in patients with oligoarthritis: results of a prospective study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70039-9

7 January 2021

10.1016/S0889-857X(05)70039-9

Identifiers

DOI

1 reference

24 August 2017

1 reference